Andrew Nyborg
Vice President, Translational Science | IND → Phase 3 & BLA Strategy | Biomarkers | BD Scientific Diligence | Building Pipelines that Survive Reality
- Role
- Vice President, Translational Science at Alumis
- Location
- Provo, UT, US
- LinkedIn followers
- 500 followers
About Andrew Nyborg
I’ve spent my career where elegant biology meets real clinical decisions. I’ve led or supported programs from early preclinical rationale through Phase 2 and Phase 3 execution, BLA submission and approval (TEPEZZA), and more recently led an IND submission and Phase 1 program for SLRN-517, culminating in a biomarker-driven decision. At ACELYRIN/Alumis, I’ve supported multiple Phase 2 programs with izokibep and lonigutimab, shaping translational strategy and clinical readouts.My focus is turning data into direction—designing biomarkers that keep programs honest, aligning clinical pharmacology with mechanism, and helping teams decide what to advance, what to fix, and what to stop. I’ve operated across startup and large-biotech environments, supporting IND planning, registrational development, and BD scientific diligence (hundreds of evaluations) from early triage to data rooms and successful partnerships and acquisitions.I’m at my best connecting mechanism → clinic → commercial value—building cross-functional teams, pressure-testing assumptions, and translating complex science for regulators, boards, investors, and partners. I value intellectual honesty, practical creativity, and programs that thrive throughout the structured chaos of discovery and development.Core strengths:Translational strategy: preclinical → IND → Phase 1/2/3 → BLABiomarker design for registrational decisionsIND planning & early clinical executionBD scientific diligence & asset evaluationScientific storytelling for governance & investors
Experience
Vice President, Translational Science
May 2025 — Present · South San Francisco, CA, US
Following ACELYRIN–Alumis merger (May 2025), continued as VP, Translational Science. Leading and supporting translational science across a clinical pipeline spanning IND through Phase 3, integrating biomarkers, clinical pharmacology, and BD diligence to enable data-driven portfolio decisions.
Education
Mayo Clinic Alix School of Medicine
Postdoctoral Fellow, Neuroscience, Neurodegeneration, Molecular and Cell Biology
2001 — 2005
Brigham Young University
PhD, Biochemistry
1996 — 2000
Boise State University
BS, Chemistry
1992 — 1996
Skills
- Protein Chemistry
- Histology
- Neuroscience
- Western Blotting
- In Vitro
- Molecular Biology
- Antibodies
- Biotechnology
- Protein Purification
- Research and Development (R&D)
- Drug Development
- Biopharmaceuticals
- Ind
- Molecular Cloning
- Animal Models
- Biochemistry
- Peptides
- In Vivo
- Pharmaceutical Industry
- Infectious Diseases
- Clinical Research
- R&D
- Pcr
- High Throughput Screening
- Drug Discovery
- Immunology
- Assay Development
- Cell
- Inflammation
- Elisa
- Life Sciences
- Lifesciences
- Purification
- Protein Expression
- Cell Culture
- Pubmed
- Cell Biology
- Fluorescence
- Biomarkers
- Vaccines
Find verified contacts for anyone on LinkedIn
Unifers gives sales teams verified emails and direct dials, enriched profiles, and outreach that lands in the inbox.
Free plan included · No credit card required
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.